OverviewSuggest Edit

Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. It operates through two segments: Diabetes and Obesity care and Biopharm. The Diabetes and Obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment covers the therapy areas of haemophilia, growth disorders, and hormone replacement therapy.

TypePublic
Founded1923
HQBagsværd, DK
Websitenovonordisk.com
Employee Ratings4.1
Overall CultureC+

Latest Updates

Employees (est.) (Sept 2020)44,326(+2%)
Job Openings747
Revenue (FY, 2019)KR122 B(+10%)
Share Price (May 2021)KR463.6
Cybersecurity ratingCMore

Key People/Management at Novo Nordisk

Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

President and Chief Executive Officer
Monique Carter

Monique Carter

Executive Vice President and Head of People & Organisation
Maziar Mike Doustdar

Maziar Mike Doustdar

Executive Vice President and Head of International Operations
Ludovic Helfgott

Ludovic Helfgott

Executive Vice President and Head of Biopharm
Karsten Munk Knudsen

Karsten Munk Knudsen

Executive Vice President and Chief Financial Officer
Doug Langa

Doug Langa

Executive Vice President and Head of North America Operations
Show more

Novo Nordisk Office Locations

Novo Nordisk has offices in Bagsværd, Hellerup, København, Køge and in 90 other locations
Bagsværd, DK (HQ)
Novo Allé 1
Hellerup, DK
Tuborg Havnevej 19
København, DK
Ørestads Blvd. 108
Køge, DK
Københavnsvej 216
Tirana, AL
EGT - Tower, Rr. "Donika Kastrioti", P. 11/1
Tizi Ouzou, DZ
Zone industrielle Aissat Idir Oued Aissi
Show all (96)

Novo Nordisk Financials and Metrics

Novo Nordisk Revenue

Embed Graph
View revenue for all periods
Novo Nordisk's revenue was reported to be kr122.02 b in FY, 2019 which is a 9.1% increase from the previous period.
DKK

Revenue (Q3, 2020)

30.9b

Gross profit (Q3, 2020)

25.8b

Gross profit margin (Q3, 2020), %

83.3%

Net income (Q3, 2020)

10.3b

EBIT (Q3, 2020)

12.8b

Market capitalization (7-May-2021)

1.1t

Closing stock price (7-May-2021)

463.6

Cash (30-Sept-2020)

25.5b

EV

1.0t
Novo Nordisk's current market capitalization is kr1.1 t.
Annual
DKKFY, 2017FY, 2018FY, 2019

Revenue

111.7b111.8b122.0b

Revenue growth, %

0%9%

Cost of goods sold

17.6b17.6b20.1b

Gross profit

94.1b94.2b101.9b
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.9b27.4b27.8b29.3b30.0b30.3b33.9b30.0b30.9b

Cost of goods sold

4.2b4.4b4.4b4.7b4.8b5.1b5.4b4.8b5.2b

Gross profit

22.7b23.1b23.3b24.6b25.2b25.2b28.5b25.2b25.8b

Gross profit Margin, %

84%84%84%84%84%83%84%84%83%
Annual
DKKFY, 2017FY, 2018FY, 2019

Cash

18.9b15.6b15.5b

Accounts Receivable

20.2b22.8b24.9b

Inventories

15.4b16.3b17.6b

Current Assets

60.1b59.1b62.5b
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

10.5b18.4b16.4b9.1b14.5b18.8b9.8b24.9b25.5b

Accounts Receivable

16.3b19.0b18.5b21.5b23.2b22.5b30.1b25.7b24.4b

Inventories

15.9b16.1b15.9b16.8b17.1b17.5b17.3b17.8b18.1b

Current Assets

49.9b57.5b54.1b52.7b58.7b63.4b63.2b73.6b73.7b
Annual
DKKFY, 2017FY, 2018FY, 2019

Net Income

38.1b38.6b39.0b

Depreciation and Amortization

3.2b3.9b5.7b

Inventories

(1.0b)(963.0m)(1.3b)

Accounts Payable

(401.0m)1.1b(398.0m)
Quarterly
DKKQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

10.8b21.1b30.1b10.4b20.0b30.2b11.9b22.5b32.8b

Depreciation and Amortization

732.0m1.5b2.3b1.1b2.2b4.3b1.1b2.2b4.4b

Cash From Operating Activities

9.8b25.6b37.2b9.9b24.9b41.6b10.0b34.3b51.8b

Purchases of PP&E

(2.1b)(4.5b)(6.9b)(2.6b)(4.8b)(7.0b)(1.7b)(2.9b)(4.3b)
DKKFY, 2017

Revenue/Employee

2.7m

Financial Leverage

2.1 x

P/E Ratio

3.4
Show all financial metrics

Novo Nordisk Operating Metrics

Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q4, 2019Q1, 2020Q2, 2020Q3, 2020Q4, 2020

Phase I Trials Products (Diabetes)

223224457

Phase II Trials Products (Diabetes)

22222221

Phase III Trials Products (Diabetes)

12246

Trials Products Submitted (Diabetes)

111
Show all operating metrics

Novo Nordisk Acquisitions / Subsidiaries

Company NameDateDeal Size
Emisphere TechnologiesNovember 06, 2020$1.4 b
CorvidiaJune 15, 2020$725 m
ZiyloAugust 20, 2018$800 m
CalibriumAugust 27, 2015
MB2 LLCAugust 27, 2015
Xellia PharmaceuticalsMay 21, 2013$700 m
Aldaph SpAOctober 01, 2003
Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd.
Churchill Stateside Solar Fund XIV, LLC
NNE A/S
Show more

Novo Nordisk Revenue Breakdown

Embed Graph

Novo Nordisk revenue breakdown by business segment: 15.7% from Biopharmaceuticals and 84.3% from Diabetes and Obesity

Novo Nordisk revenue breakdown by geographic segment: 49.5% from North America and 50.5% from International

Show all human capital metrics

Novo Nordisk Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Novo Nordisk Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Novo Nordisk Online and Social Media Presence

Embed Graph

Novo Nordisk Company Culture

  • Overall Culture

    C+

    65/100

  • CEO Rating

    B

    70/100

  • Compensation

    C+

    64/100

  • Diversity

    B

    71/100

Learn more on Comparably

Novo Nordisk News and Updates

Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021

Bagsværd, Denmark, 7 May 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme

Bagsværd, Denmark, 7 May 2021 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2021 share repurchase programme of up to a total of DKK 18 billion to …

Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021

Bagsværd, Denmark, 29 April 2021 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Novo Nordisk A/S – Reduction of the share capital

Bagsværd, Denmark, 27 April 2021 – At Novo Nordisk’s Annual General Meeting on 25 March 2021, it was decided to reduce the company’s B share capital from DKK 362,512,800 to DKK 354,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 8,000,000 di…

Clinical Trial Market Revenue to Cross $69.94 by 2027 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by Clinipace, Novo Nordisk, Pfizer, Sanofi, F. Hoffmann-La Roche Ltd, Alcami Corporation and Accell Clinical Research

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Data Bridge Market Research has recently published the Global Clinical Trials Market the study provides an overview of current statistics and future predictions of the Global Clinical Trials Market. The study highlights a detailed assessment of the…

Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg.
Show more

Novo Nordisk Frequently Asked Questions

  • When was Novo Nordisk founded?

    Novo Nordisk was founded in 1923.

  • Who are Novo Nordisk key executives?

    Novo Nordisk's key executives are Lars Fruergaard Jørgensen, Monique Carter and Maziar Mike Doustdar.

  • How many employees does Novo Nordisk have?

    Novo Nordisk has 44,326 employees.

  • What is Novo Nordisk revenue?

    Latest Novo Nordisk annual revenue is kr122 b.

  • What is Novo Nordisk revenue per employee?

    Latest Novo Nordisk revenue per employee is kr2.8 m.

  • Who are Novo Nordisk competitors?

    Competitors of Novo Nordisk include Mankind Pharma, Abbott and Amgen.

  • Where is Novo Nordisk headquarters?

    Novo Nordisk headquarters is located at Novo Allé 1, Bagsværd.

  • Where are Novo Nordisk offices?

    Novo Nordisk has offices in Bagsværd, Hellerup, København, Køge and in 90 other locations.

  • How many offices does Novo Nordisk have?

    Novo Nordisk has 96 offices.